High-resolution mass spectrometry proteomics for the identification of candidate plasma protein biomarkers for chronic obstructive pulmonary disease

York, Timothy P.; Oord, Edwin J. C. G. van den; Langston, Timothy B.; Edmiston, Jeffery; McKinney, William T.; Webb, Bradley T.; Murrelle, E. Lenn; Zedler, Barbara; Flora, Jason W.

doi:10.3109/13547501003789901

Cited by 10 publications

(13 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of note, several of the 31 differentially expressed proteins in the COPD discovery group have been reported previously using either immunoassay or mass spectroscopy methods (13,15,19,21,31). Specifically, we observed increases in COPD of acute phase response proteins e.g., CRP, fibrinogen; coagulation factors e.g., coagulation factor V; adhesion molecules e.g., VCAM-1; and decreases in molecules involved in protease-induced lung tissue injury and repair e.g., TIMP-1 and TIMP-2 (13,15,19,21,31).…”

Section: Discussionmentioning

confidence: 99%

“…In fact, the GeLC-MS/MS method allowed greater coverage of the plasma proteome in COPD than prior studies which utilized 2-D gel electrophoresis or strong cation exchange chromatography (21,29–31). Specifically, we detected over 700 unique proteins which included several differentially expressed proteins whose concentrations are in the ng/mL range e.g., GRP78, sCD163, MSTP9, IL1AP, TIMP1, ICAM1, proteoglycan 4, etc.…”

Section: Discussionmentioning

confidence: 99%

“…In contrast, prior mass spectroscopy studies have observed differences in proteins whose concentration is in the mg/mL range, e.g., haptoglobin, fibrinogen, hemopexin, ceruloplasmin, complement components, etc. (21,29–31). …”

Section: Discussionmentioning

confidence: 99%

“…To date, a limited number of studies of the serum or plasma proteome in COPD have been performed using mass spectroscopy (21,29–31). These have utilized sample fractionation methods which essentially identify only high abundance plasma proteins like acute phase reactants, coagulation factors, and complement components, etc.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Analysis of the Plasma Proteome in COPD: Novel Low Abundance Proteins Reflect the Severity of Lung Remodeling

Merali

Barrero

Bowler

et al. 2013

COPD: Journal of Chronic Obstructive Pulmonary Disease

View full text Add to dashboard Cite

The search for COPD biomarkers has largely employed a targeted approach that focuses on plasma proteins involved in the systemic inflammatory response and in lung injury and repair. This proof of concept study was designed to test the idea that an open, unbiased, in-depth proteomics approach could identify novel, low abundance plasma proteins i.e., ng/mL concentration, which could serve as potential biomarkers. Differentially expressed proteins were identified in a discovery group with severe COPD (FEV1 <45% predicted; n = 10). Subjects with normal lung function matched for age, sex, ethnicity and smoking history served as controls (n = 10). Pooled plasma from each group was exhaustively immunodepleted of abundant proteins, d separated by 1-D gel electrophoresis and extensively fractionated prior to LC-tandem mass spectroscopy (GeLC-MS). Thirty one differentially expressed proteins were identified in the discovery group including markers of lung defense against oxidant stress, alveolar macrophage activation, and lung tissue injury and repair. Four of the 31 proteins (i.e., GRP78, soluble CD163, IL1AP and MSPT9) were measured in a separate verification group of 80 subjects with varying COPD severity by immunoassay. All 4 were significantly altered in COPD and 2 (GRP78 and soluble CD163) correlated with both FEV1 and the extent of emphysema. In-depth, plasma proteomic analysis identified a group of novel, differentially expressed, low abundance proteins that reflect known pathogenic mechanisms and the severity of lung remodeling in COPD. These proteins may also prove useful as COPD biomarkers.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Analysis of the Plasma Proteome in COPD: Novel Low Abundance Proteins Reflect the Severity of Lung Remodeling

Merali

Barrero

Bowler

et al. 2013

COPD: Journal of Chronic Obstructive Pulmonary Disease

View full text Add to dashboard Cite

show abstract

“…Interestingly, circulating TF procoagulant activity is elevated and constitutes a prothrombotic and proinflammatory state in stable but moderate-severe COPD [80]. Finally, high-resolution mass spectrometry proteomics identified proteins of the coagulation cascade as prime biomarkers of COPD [81].…”

Section: Atherosclerosis and Copdmentioning

confidence: 98%

The Role of Coagulation in Chronic Inflammatory Disorders: A Jack of All Trades

Borensztajn¹,

Thüsen²,

Spek³

2011

Current Pharmaceutical Design

View full text Add to dashboard Cite

Chronic inflammatory disorders constitute a heterogeneous group of complex and multifactorial diseases, which are often associated with increased cardiovascular morbidity and mortality, independent of the established cardiovascular risk factors. In keeping with this observation, hypercoagulability is frequently observed in patients suffering from atherosclerosis, chronic obstructive pulmonary disease and rheumatoid arthritis although the physiological significance of activated coagulation remained elusive. However, the identification of protease activated receptors (PAR) seem to provide a link between coagulation activation and disease progression as their activation by coagulation factors triggers a broad range of signaling pathways relevant for chronic inflammatory disorders. In experimental animal models, anticoagulation and/or genetic ablation of PAR signaling affords protection against the perpetuation of atherosclerosis, chronic obstructive pulmonary disease and rheumatoid arthritis. It is thus tempting to speculate that targeting the coagulation-PAR axis might have clinical relevance in the setting of chronic inflammatory disorders. In the current review, we discuss the current knowledge on coagulation activation in inflammatory disorders, we discuss the relationship between atherosclerosis, chronic obstructive pulmonary disease and rheumatoid arthritis and we review the current knowledge on PAR signaling in these disorders.

show abstract

Evaluation of common protein biomarkers involved in the pathogenesis of respiratory diseases with proteomic methods: A systematic review

Rezaeeyan,

Arabfard,

Rasouli

et al. 2023

Immunity Inflam & Disease

View full text Add to dashboard Cite

AimRespiratory disease (RD) is one of the most common diseases characterized by lung dysfunction. Many diagnostic mechanisms have been used to identify the pathogenic agents of responsible for RD. Among these, proteomics emerges as a valuable diagnostic method for pinpointing the specific proteins involved in RD pathogenesis. Therefore, in this study, for the first time, we examined the protein markers involved in the pathogenesis of chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), asthma, bronchiolitis obliterans (BO), and chemical warfare victims exposed to mustard gas, using the proteomics method as a systematic study.Materials and MethodsA systematic search was performed up to September 2023 on several databases, including PubMed, Scopus, ISI Web of Science, and Cochrane. In total, selected 4246 articles were for evaluation according to the criteria. Finally, 119 studies were selected for this systematic review.ResultsA total of 13,806 proteins were identified, 6471 in COPD, 1603 in Asthma, 5638 in IPF, three in BO, and 91 in mustard gas exposed victims. Alterations in the expression of these proteins were observed in the respective diseases. After evaluation, the results showed that 31 proteins were found to be shared among all five diseases.ConclusionAlthough these 31 proteins regulate different factors and molecular pathways in all five diseases, they ultimately lead to the regulation of inflammatory pathways. In other words, the expression of some proteins in COPD and mustard‐exposed patients increases inflammatory reactions, while in IPF, they cause lung fibrosis. Asthma, causes allergic reactions due to T‐cell differentiation toward Th2.

show abstract

High-resolution mass spectrometry proteomics for the identification of candidate plasma protein biomarkers for chronic obstructive pulmonary disease

Cited by 10 publications

References 60 publications

Analysis of the Plasma Proteome in COPD: Novel Low Abundance Proteins Reflect the Severity of Lung Remodeling

Analysis of the Plasma Proteome in COPD: Novel Low Abundance Proteins Reflect the Severity of Lung Remodeling

The Role of Coagulation in Chronic Inflammatory Disorders: A Jack of All Trades

Evaluation of common protein biomarkers involved in the pathogenesis of respiratory diseases with proteomic methods: A systematic review

Contact Info

Product

Resources

About